Takeda Pharmaceutical Co Ltd (4502.T)
4,610JPY
2 Jul 2013
¥50 (+1.10%)
¥4,375
¥4,620
¥4,620
¥4,585
1,766,200
3,944,685
¥5,520
¥3,490
4502.T
About
Overall
| Beta: | 0.60 |
| Market Cap (Mil.): | ¥3,600,878.00 |
| Shares Outstanding (Mil.): | 789.67 |
| Dividend: | 90.00 |
| Yield (%): | 3.95 |
Financials
| 4502.T | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 27.43 | 32.01 | 32.18 |
| EPS (TTM): | 166.23 | -- | -- |
| ROI: | 4.42 | 19.61 | 18.91 |
| ROE: | 6.29 | 20.45 | 19.87 |
Update-Moody's Moody's assigns (P)Aa3 to Takeda Pharmaceutical's domestic shelf registration programme
For the full text of this story please click the following link:
Takeda CEO backs Abe's growth plans, seeks more globalised Japan
TOKYO - Top Japanese businessman Yasuchika Hasegawa backs Prime Minister Shinzo Abe's plans to revitalize the stagnant economy in the face of criticism that the government is sidestepping politically thorny reforms ahead of an upper house election.
UPDATE 2-Teva, Sun Pharma to pay $2.15 bln to settle Pfizer patent suit
* Teva to pay $1.8 bln, half this year and rest by Oct 2014
CORRECTED-Amag investigates anemia drug after report of death in Switzerland
(Corrects headline to "investigates." Amag did not say the drug caused the fatality.)
Amag says anemia drug caused fatal reaction in Switzerland
- Amag Pharmaceuticals Inc said its marketing partner in Switzerland, Takeda Pharmaceutical Co Ltd, is recalling a batch of Amag's anemia drug, Rienso, because of a death and several cases of hypersensitivity.
Amag says anemia drug caused fatal reaction in Switzerland
May 21 - Amag Pharmaceuticals Inc said its marketing partner in Switzerland, Takeda Pharmaceutical Co Ltd, is recalling a batch of Amag's anemia drug, Rienso, because of a death and several cases of hypersensitivity.
Lundbeck says drug shows improvement in depression symptoms
COPENHAGEN, May 18 - Danish pharmaceutical group Lundbeck and Japanese partner Takeda said on Saturday that data from clinical phase III studies with the antidepressant vortioxetine had shown significant improvement in patients' symptoms.
NPS regains right to drugs from Takeda for $50 mln in NPS shares
March 19 - NPS Pharmaceuticals Inc has regained full worldwide rights to a pair of drugs from Japan's Takeda Pharmaceutical Co in exchange for $50 million in NPS common shares, the companies announced on Tuesday.
BRIEF-Takeda submits marketing authorisation application for vedolizumab in European union
LONDON, March 8 - Takeda Pharmaceutical Co Ltd : * Submits marketing authorisation application for vedolizumab in moderately to
Affymax, Takeda recall anemia drug Omontys after deaths
TOKYO/WASHINGTON - U.S.-based Affymax Inc and Japan's Takeda Pharmaceutical Co said they are voluntarily recalling all lots of anemia treatment Omontys (peginesatide) in the United States due to reports of serious hypersensitivity reactions, including some deaths.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Wright Reports
|
$483.00
|
|
Provider: Datamonitor
|
$175.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
